Janssen Sciences Ireland UC, of Cork, Ireland, a unit of Johnson & Johnson, said a regimen of two investigational long-acting, injectable formulations of HIV medicines – Janssen's rilpivirine and Viiv Healthcare's cabotegravir – given together every four or eight weeks was as effective as three-drug oral antiretroviral therapy at maintaining HIV-1 viral suppression through 96 weeks (HIV-1 RNA